OCEANSIDE, Calif. & ST. PETERSBURG, Fla. - eTradeWire -- Breathe Biologics, Inc.(www.BreatheBiologics.com) names Ed Johnson as Chief Executive Officer.

Mr. Johnson is a seasoned biotech executive and company builder with a track record of leading organizations at the intersection of science, regulation, and commercialization. He has served in multiple C-suite roles—including Chief Executive Officer, Chief Operating Officer, and Chief Marketing Officer—guiding companies from early development through global market engagement.

In 2020, Mr. Johnson founded and led iOneBioUSA Molecular COVID-19 Technologies, where he worked directly with FDA research and regulatory frameworks while coordinating multinational collaborations with medical laboratories, hospitals, and researchers across North America, Europe, the Middle East, Africa, and Asia. His leadership focused on speed, scientific rigor, and scalable execution during a period of unprecedented global demand.

More on eTradeWire News

• FACITI Launches AI Replicants for Small Service Businesses — Live in 24 Hours
• Best Self Defense Classes in Boynton Beach: 40+ Year Expert GM Pedro Rodriguez
• San Diego Med Spa Champions "Natural Botox" Movement, Prioritizing Subtle, Authentic Enhancements
• New Platform Solves the UK Padel Booking Problem
• Exclusive Workshop : Step into your next version

Previously, Mr. Johnson held leadership roles at Bristol Myers Squibb, contributing to the launch of five-branded pharmaceutical products across multiple therapeutic areas. Over the past decade, he has advised numerous life sciences, medical device, and pharmaceutical companies on commercialization strategy, corporate development, and investor positioning. Most recently, he served as an independent director of a publicly traded SPAC, helping complete the successful acquisition of a next-generation medical device company—demonstrating his ability to drive value creation in both private and public market environments.

About Breathe Biologics, Inc.:

Breathe Biologics, Inc. is a regenerative medicine company focused on lung diseases using licensed and patented umbilical cord derived multi-potent mesenchymal stem cell, termed "JadiCell."

As published in the Journal for Stem Cells Translational Medicine, , January, 2021, "Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS"

The clinical trial yielded significant improvements in patient survival and recovery speed compared to standard care:

• Patient Survival: The JadiCell group achieved a 91% survival rate compared to 42%  in the control group.
• 100% Effectiveness: Data indicated a 100% survival rate for patients under the age of 85 treated with JadiCells.
• Recovery Speed: More than half of treated patients recovered and were home within two weeks, showing a significantly faster recovery time than the control group.
• Safety: There were no infusion-related serious adverse events (SAEs), and the JadiCell group had significantly better SAE-free survival.
• Jadi-Cells do Not possess oncogenes.  Oncogenes cause cells to grow and divide uncontrollably, which can lead to cancer.
• http://www.BreatheBiologics.com

More on eTradeWire News

• Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
• Youngstown, Ohio Startup Launches AI-Powered Quarterback Coaching Platform
• PPC for SEO Course Gains Strong Industry Response
• 13 Full Moons of Black Dandelion Convergent Voice™ An Integration of Literacy & Wellness Symposium
• Emperor of the Cherokee: A Novel Debuts